BR112023014826A2 - Agentes de ligação de hhla2 com nova atividade - Google Patents
Agentes de ligação de hhla2 com nova atividadeInfo
- Publication number
- BR112023014826A2 BR112023014826A2 BR112023014826A BR112023014826A BR112023014826A2 BR 112023014826 A2 BR112023014826 A2 BR 112023014826A2 BR 112023014826 A BR112023014826 A BR 112023014826A BR 112023014826 A BR112023014826 A BR 112023014826A BR 112023014826 A2 BR112023014826 A2 BR 112023014826A2
- Authority
- BR
- Brazil
- Prior art keywords
- hhla2
- binding agents
- new activity
- activity
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142832P | 2021-01-28 | 2021-01-28 | |
| PCT/US2022/014423 WO2022165258A1 (en) | 2021-01-28 | 2022-01-28 | Hhla2 binding agents with novel activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023014826A2 true BR112023014826A2 (pt) | 2023-10-03 |
Family
ID=82652818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023014826A BR112023014826A2 (pt) | 2021-01-28 | 2022-01-28 | Agentes de ligação de hhla2 com nova atividade |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250270323A1 (https=) |
| EP (1) | EP4284431A4 (https=) |
| JP (1) | JP2024509501A (https=) |
| KR (1) | KR20230135637A (https=) |
| CN (1) | CN116981476A (https=) |
| AU (1) | AU2022214939A1 (https=) |
| BR (1) | BR112023014826A2 (https=) |
| CA (1) | CA3207494A1 (https=) |
| IL (1) | IL304584A (https=) |
| MX (1) | MX2023008182A (https=) |
| WO (1) | WO2022165258A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054560A2 (en) * | 2023-09-08 | 2025-03-13 | Nextpoint Therapeutics, Inc. | Antibody-drug conjugates |
| CN119841949A (zh) * | 2023-10-17 | 2025-04-18 | 科辉智药(深圳)新药研究中心有限公司 | 一种抗人hhla2的纳米抗体及其应用 |
| CN121005781A (zh) * | 2024-05-24 | 2025-11-25 | 合肥天港免疫药物有限公司 | 高亲和力b7h7抗体或其抗原结合片段及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015167948A1 (en) * | 2014-04-30 | 2015-11-05 | Albert Einstein College Of Medicine Of Yeshiva University | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies |
| AU2018296067B2 (en) * | 2017-07-06 | 2021-06-10 | Merus B.V. | Binding molecules that modulate a biological activity expressed by a cell |
| JP7429192B2 (ja) * | 2018-04-06 | 2024-02-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用 |
-
2022
- 2022-01-28 MX MX2023008182A patent/MX2023008182A/es unknown
- 2022-01-28 CN CN202280012137.1A patent/CN116981476A/zh active Pending
- 2022-01-28 EP EP22746752.9A patent/EP4284431A4/en active Pending
- 2022-01-28 JP JP2023544261A patent/JP2024509501A/ja active Pending
- 2022-01-28 KR KR1020237028708A patent/KR20230135637A/ko active Pending
- 2022-01-28 CA CA3207494A patent/CA3207494A1/en active Pending
- 2022-01-28 US US18/263,313 patent/US20250270323A1/en active Pending
- 2022-01-28 BR BR112023014826A patent/BR112023014826A2/pt unknown
- 2022-01-28 AU AU2022214939A patent/AU2022214939A1/en active Pending
- 2022-01-28 WO PCT/US2022/014423 patent/WO2022165258A1/en not_active Ceased
-
2023
- 2023-07-19 IL IL304584A patent/IL304584A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250270323A1 (en) | 2025-08-28 |
| EP4284431A4 (en) | 2025-01-15 |
| KR20230135637A (ko) | 2023-09-25 |
| IL304584A (en) | 2023-09-01 |
| JP2024509501A (ja) | 2024-03-04 |
| EP4284431A1 (en) | 2023-12-06 |
| CA3207494A1 (en) | 2022-08-04 |
| CN116981476A (zh) | 2023-10-31 |
| WO2022165258A1 (en) | 2022-08-04 |
| MX2023008182A (es) | 2023-09-15 |
| AU2022214939A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023014826A2 (pt) | Agentes de ligação de hhla2 com nova atividade | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| BR112021019748A2 (pt) | Degradadores de stat e usos dos mesmos | |
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| MX2025009222A (es) | Agentes de union a clec9a y su uso | |
| PY1917867A (es) | Picolinamidas como fungicidas | |
| BR112022003527A2 (pt) | Cianopirrolidinas substituídas com atividade como inibidores de usp30 | |
| CY1119030T1 (el) | Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων | |
| BR112022001415A2 (pt) | Agentes interleucina-2 e os usos dos mesmos | |
| BR112019021277A8 (pt) | Curativos extensíveis | |
| EP3852032C0 (en) | FIRST MACHINE APPROACH FOR IDENTIFYING ACCESSIBILITY, NONCONFORMITIES, REMEDIATION AND FIXATION TECHNIQUES DURING RUNTIME | |
| BR112015023557A2 (pt) | proteínas de ligações dual específicas direcionadas contra tnfa | |
| EA201001628A1 (ru) | Модифицированные полипептиды фактора vii и их применение | |
| BR112023015050A2 (pt) | Anticorpos anti-met e usos dos mesmos | |
| EP2596122A4 (en) | MODULATORS OF SIRT5 AND TESTS FOR SCREENING | |
| BR112022017192A2 (pt) | Variantes de transglutaminase | |
| BR112015023074A2 (pt) | agentes de ligação-met e uso dos mesmos | |
| EP3934632A4 (en) | Esketamine for the treatment of depression | |
| BR112022008287A2 (pt) | Métodos de tratamento usando um modulador de mtorc1 | |
| IL286996B (en) | Device for electrotherapy and/or electrophysiology, kit and assembly | |
| BR112023021034A2 (pt) | Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos | |
| BR112019021325A8 (pt) | Curativos extensíveis | |
| BR112022011147A2 (pt) | Compostos para inibir fatores de neovascularização e uso dos mesmos | |
| BR112021018611A2 (pt) | Anticorpos tendo especificidade para btn2 e usos dos mesmos | |
| BR112022000005A2 (pt) | Agentes de ligação a cd38 e usos dos mesmos |